A Protocol for Generation of Clinical Grade mRNA-Transfected Monocyte-Derived Dendritic Cells for Cancer Vaccines

Scandinavian Journal of Immunology

Volumn 58, Issue 5, 2003, Pages 578-586

  Mu, L J ^a   Gaudernack, G ^a   Saeboe Larssen S ^a   Hammerstad, H ^a   Tierens, A ^a   Kvalheim, G ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD19 ANTIGEN; CD2 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; POLITEF; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLOOD CELL; CANCER CELL CULTURE; CELL MATURATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DENDRITIC CELL; DEVICE; ELECTROPORATION; ENZYME IMMUNOASSAY; FEMALE; FREEZING; GAS PERMEABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; IN VITRO STUDY; LEUKAPHERESIS; LYMPHOCYTE CULTURE; LYMPHOCYTE DEPLETION; MALE; MONOCYTE; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; THAWING; TIME;

ADULT; CANCER VACCINES; CRYOPRESERVATION; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOPHENOTYPING; LYMPHOCYTE DEPLETION; MALE; MONOCYTES; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFECTION;

EID: 0242574478     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01333.x     Document Type: Article

References (27)

1. Lilleby W, Nesland JM, Fosså SD et al. The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer. Int J Cancer 2003;103:91-6.
2. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
3. Banchereau J, Steinman RM. Dendritic Cells and the Control of Immunity. Nature 1998;392:245-52.
4. Boczkowski D, Nair SK, Nam J-H et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000;60:1028-34.
5. Heiser A, Dahm P, Yancey DR et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL response in vitro. J Immunol 2000;164:5508-14.
6. Ritchie DS, Hermans IF, Lumsden JM et al. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J Immunol Methods 2000;246:109-17.
7. Lambert LA, Gibson GR, Maloney M et al. Intronodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001;61:641-6.
8. Nestle FO, Alijagoc S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
9. Morse MA, Coleman RE, Akabani G et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56-8.
10. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
11. Nouri-Shirazi M, Banchereau J, Bell D et al. Dendritic cells capture killed tumor cells and present their antigen to elicit tumor-specific immune responses. J Immunol 2000;165:3797-803.
12. Suen Y, Lee S-M, Aono F et al. Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy 2001;5:365-72.
13. Boczkowski D, Nair SK, Snyder D et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72.
14. Mitchell DA, Nair SK. RNA transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000;106:1065-9.
15. Sæbøe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002;1:191-203.
16. Thurner B, Røder C, Dieckmann D et al. Generation of large numbers of mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
17. Bender A, Sapp M, Schuler G et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996;196:121.
18. Maria RM, Samantha C, Simonetta R et al. Generation of dendritic cells from CD14 monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol 2003;121:240-50.
19. Wong ECC, Maher VE, Hines K et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001;1:19-29.
20. Wong ECC, Lee SM, Hines K et al. Development of a closed-system process for clinical-scale generation of DCs: evaluation of two monocyte-enrichment methods and two culture containers. Cytotherapy 2002;1:65-76.
21. Romani N, Reider DH, Ebner MS. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-51.
22. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic cell-based vaccines. Cancer Immunol Immunother 1998;46:82-7.
23. Van Tendeloo VF, Ponsaerts P, Lardon F et al. Highly efficient gene delivery by mRNA electroporation in human haematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001;98:49-56.
24. + T cells using an ELISPOT assay. J Immunol Methods 1995;181:45-54.
25. + cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 1991;3:579-85.
26. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981;126:1614-9.
27. Reid CDL. Review dendritic cells and immunotherapy or malignant disease. Br J Haematol 2001;112:874-87.